WO2012134252A2 - Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis - Google Patents

Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis Download PDF

Info

Publication number
WO2012134252A2
WO2012134252A2 PCT/KR2012/002469 KR2012002469W WO2012134252A2 WO 2012134252 A2 WO2012134252 A2 WO 2012134252A2 KR 2012002469 W KR2012002469 W KR 2012002469W WO 2012134252 A2 WO2012134252 A2 WO 2012134252A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
kidney cancer
extract
present
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002469
Other languages
English (en)
Korean (ko)
Other versions
WO2012134252A3 (fr
Inventor
황성연
정경채
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Bio Medical Science Institute Co Ltd
Original Assignee
Korea Bio Medical Science Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Bio Medical Science Institute Co Ltd filed Critical Korea Bio Medical Science Institute Co Ltd
Publication of WO2012134252A2 publication Critical patent/WO2012134252A2/fr
Publication of WO2012134252A3 publication Critical patent/WO2012134252A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Definitions

  • the present invention relates to a novel use of madin extract. Specifically, the present invention relates to a therapeutic composition and functional food containing as soon as the active ingredient extract showing excellent prophylactic or therapeutic efficacy against kidney cancer.
  • the kidney is an important urinary system that has the role of excreting waste products in vitro by filtering blood to produce urine. At the same time, it is also an important endocrine organ that produces hormones such as angiotensin, which regulates blood pressure, and erythropoietin, a red blood cell hematopoietic factor. Renal tumors include kidney cell cancer in adults, Wilms' tumor in children, and sarcoma as a rare tumor, but the most common malignancy below Renal cell cancer, a tumor, is called kidney cancer. The incidence of renal cancer is about 2.5 per 100,000 population, and male to female ratio is 2 to 3: 1. Among urological malignancies, there are many tumors following prostate cancer and bladder cancer.
  • kidney cancer Genetic factors are also known as risk factors for kidney cancer, but generally include smoking and excessive fat intake. It is also known that the incidence of such tumors is high in patients undergoing long-term dialysis. In kidney cancer, when the tumor has a maximum diameter of 5 cm or less, some subjective symptoms rarely occur and are often found by CT scan or the like at the time of examination. Larger tumors may include hematuria, abdominal tumors, and pain. In addition, systemic symptoms may cause fever, weight loss, anemia and the like, and rarely, endocrine factors may cause erythrocytosis, hypertension, hypercalcemia, and the like.
  • vein veins of the abdominal body surface or venous varicose veins occur due to the progression of kidney cancer into the inferior vena cava.
  • About 20% of kidney cancers are found from lung or bone metastases.
  • tumors tend to spread in veins, and metastasis to other organs is likely to occur.
  • VHL von-Hippel-Lindau
  • the main treatment for kidney cancer is surgical therapy. Regardless of the timing of the disease, extraction of the kidneys or partial extraction of the kidneys is the most common where possible, and even if there is metastasis, surgical removal of the kidneys may be considered.
  • Arterial embolization of the renal artery may be used as a method other than the surgical therapy. This method may be performed prior to surgery in cases where it is impossible to extract or when a large tumor is removed.
  • Recent advances in burn diagnostics have led to early detection of renal cancer, even at very small sizes, resulting in more than 90% healing in early cancer. However, since the therapeutic results of large tumors larger than 5 cm or tumors with metastases are poor (the 5-year survival rate of all renal cell carcinomas is about 50 to 60%), the importance of early detection is recognized.
  • Cannabis Semen is a dried seed of Cannabis sativa L. of the genus Moraceae, whose origin is the annual herb of Central Asian origin, whose main stem is 1-2.5 m high and grows straight. With fine hairs and green. The leaves are vivid at the bottom, long lobes, long intestinal bile divided into 5-9, but the upper part is shorted without splitting or splitting into three.
  • Tetrahydrocannabinol known as hemp, has psychotropic effects and initially produces pleasure and hallucination with the central nervous system and cerebral spinal cord, which pass into paralysis. At the same time, the dense horse comes to the sensory spirits, bringing about the loss of pain, and eventually reaches the communist zone.
  • constipation As soon as it is intestine moisturizes, and combined with passersby, peony, fruit room, rhubarb, bakbak is used to treat constipation. In other words, as soon as the chapter through the stools to come out well. It can be applied to constipation (Park Jong-hee, co-author Lee Jeong-gyu, commercial medicinal plant illustration, p199-p201). As soon as it is dry, it helps to smoothly communicate the intestines and improves blood circulation.
  • Cannabis Semen is a seed of hemp ( cannabis sativa L.) (Moraceae) used for the purpose of yunjangcheong, hemophilia, intestinal constipation, gastrointestinal tightening, medicinal constipation in Oriental medicine and private.
  • Korean Unexamined Patent Publication No. 2003-0059951 includes herbal extracts containing mazain, that is, extracts consisting of rhubarb, charcoal, Ukriin, betel nut, mazain, earth and sand, hyssop, powder, cornus, fruit juice, windproof and poisonous.
  • a composition for preventing and treating diabetes is disclosed, and
  • Korean Laid-Open Patent Publication No. 1999-0084271 discloses a tea having a constipation symptom improvement effect including mazain and a method for manufacturing the same.
  • 0630410 discloses a topical composition for the prevention and treatment of acne containing the extract of Mazarin.
  • the present invention relates to a composition containing the herbal extract having the ability to inhibit the growth of the ear, synagogues, maine, white oysters and corydalis showing a proliferation inhibitory effect of P. acnes at low concentrations.
  • the herbal extract having the ability to inhibit the growth of the ear, synagogues, maine, white oysters and corydalis showing a proliferation inhibitory effect of P. acnes at low concentrations.
  • the present inventors completed the present invention by confirming that the extract of the mother can effectively kill kidney cancer cells during the study of herbal medicine for the mother.
  • the present invention provides a composition for the prevention and treatment of kidney cancer, including the active ingredient extracted with Cannabis Semen ( Cannabis Semen ) as an organic solvent.
  • the organic solvent is preferably ethanol.
  • the present invention provides a functional food for preventing kidney cancer containing as soon as ethanol extract as an active ingredient containing a food supplement acceptable food supplement.
  • the present invention provides a composition for the prevention and treatment of kidney cancer containing Cannabis Semen ethanol extract as an active ingredient.
  • the composition of the present invention comprises a extract as soon as the active ingredient, and may further comprise a pharmaceutically acceptable carrier or diluent.
  • the ethanol extract is preferably extracted at 50 ° C. for 24 hours, wherein the ethanol extract is more preferably dried and concentrated at 45 ° C. under reduced pressure, and the ethanol Is most preferably 95%.
  • the kidney cancer is preferably renal cell cancer.
  • the extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane.
  • Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.
  • the ethanol extract may be prepared by filtering.
  • the filtrate obtained by filtering the extract may be concentrated under reduced pressure.
  • the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.
  • the "pharmaceutically acceptable carrier” is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.
  • the composition for treating kidney cancer of the present invention may be prepared as a medicament by adding one or more pharmaceutically acceptable carriers together with the active ingredient.
  • the carrier may include, but is not limited to, saline, buffered saline, water, glycerol and ethanol, and any suitable agent known in the art (Remingtons's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA) may be used. .
  • Formulations for the formulation of the extract of the present invention can be administered orally during clinical administration and can be used in the form of general pharmaceutical formulations, when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants And diluents such as surfactants or excipients.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc.
  • liquid preparations for oral use include suspensions, solvents, emulsions, and syrups.
  • various excipients may be included, such as wetting sweeteners, fragrances, preservatives and the like.
  • the herbal medicine that may be added to the composition of the present invention may be any pharmaceutically acceptable herbal medicine, for example, Angelica tenuissimae Radix, Gastrodiae Rhizoma, Bapleuri Radix, Angelica ( Angelicae gigantis Radix, Persicae Semen, Cinnamomi Ramulus, Rhubarb (Rhei Rhizoma), Licorice (Glycyrrhizae Radix), Cnidii Rhizoma, Aurantii nobilis Pericarpium, Taxa (Alismatis Rhizoma) Coptidis Rhizoma, Scutellariae Radix, Hoelen, Peeoniae Radix, Atractylodis Rhizoma alba, Phellodendri Cortex, Gardeniae Fructus, Pinelliae Tuber, Ramulu Set (Uncaria) Uncus, Ponciri Fructus, Ginseng, Gingseng, Liriopis Tuber, Poly
  • composition of the present invention may be administered in various parenteral formulations during actual clinical administration, and solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • solid preparations include tablets, pills, powders, granules, capsules, and the like.
  • excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
  • preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • calcium or vitamin D 3 may be added to enhance the efficacy of the treatment.
  • Such compositions may be presented in unit-dose (single) or multi-dose (several) containers, such as sealed ampoules and vials, and immediately before use, sterile liquid carriers such as water for injection Can be stored under freeze-drying conditions requiring only the addition of. Immediate injection solutions and suspensions can be prepared from sterile powders, granules and tablets.
  • the formulations of the present invention can be applied differently depending on the age, sex, condition of the subject, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the drug used in combination.
  • the invention also includes formulations of dosage units.
  • the formulations are present in individual dosage forms, such as tablets, coated tablets, capsules, pills, suppositories, and ampoules, wherein the amount of active compound in the drug corresponds to the fraction or multiple of the individual dosage.
  • Dosage units may contain, for example, one, two, three or four times the individual dosage, or 1/2, 1/3 or 1/4 times.
  • the individual dosages preferably contain an amount in which the active compound is administered at one time, which usually corresponds to all, 1/2, 1/3 or 1/4 times the daily dosage.
  • extract refers to an active ingredient isolated from natural products.
  • the extract may be obtained by an extraction process using water, an organic solvent, or a mixed solvent thereof, and includes an extract, a dry powder thereof, or any form formulated using the same.
  • the ethanol extract of mazain killed 89.9% of ACHN kidney cancer cells at 100 ⁇ g / ml and the EC 50 (half maximal effective concentration) was 39.7 ⁇ g / ml.
  • the above results demonstrate that the extract of the present invention has excellent killing activity of ACHN renal cancer cells, and further has renal cancer treatment and prophylactic activity.
  • prevention means any action that inhibits or delays the development of kidney cancer by administration of the composition.
  • treatment means any action that improves or advantageously changes the symptoms of kidney cancer by administration of the composition.
  • the extract in the present invention can be extracted using water, an organic solvent, or a mixed solvent thereof.
  • an organic solvent in particular ethanol.
  • the extracted solution can be used directly or can be concentrated and / or dried.
  • methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,3-butylene glycol, propylene glycol, or a mixed solvent thereof may be used and extracted by room temperature or warming under conditions where the active ingredient of the herbal medicine is not destroyed or minimized.
  • the degree of extraction and loss of the active ingredient of the drug may vary, so select an appropriate organic solvent.
  • the extraction method is not particularly limited, and examples thereof include cold needle extraction, ultrasonic extraction, reflux cooling extraction, and the like.
  • Filtration is a process of removing the suspended solid particles from the extract, it may be used to filter the particles using cotton, nylon or the like, or may be used, such as ultrafiltration, cryofiltration, centrifugal separation, but is not limited thereto.
  • Concentration of the extract may be used, such as concentrated under reduced pressure, reverse osmosis concentration.
  • the drying step after concentration includes freeze drying, vacuum drying, hot air drying, spray drying, reduced pressure drying, foam drying, high frequency drying, infrared drying, and the like. If desired, a process of grinding the final dried extract may be added.
  • the extract can perform an additional fractionation process.
  • the extract is suspended in distilled water to obtain a nonpolar solvent soluble layer by extraction and separation with a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • a nonpolar organic solvent such as hexane, ether, dichloromethane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be used by concentrating and / or drying it.
  • the term "pharmaceutically acceptable salts” means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases.
  • suitable acids include hydrochloric acid, bromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , Benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
  • Salts derived from suitable bases may include alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium and the like.
  • the pharmaceutical composition for preventing and treating kidney cancer diseases of the present invention comprises 0.1 to 50% by weight of the extract or compound based on the total weight of the composition.
  • the composition does not increase the efficacy, but may include additional ingredients that are commonly used in the pharmaceutical composition to improve the smell, taste, time and the like.
  • the composition adds inorganic and organic additives such as vitamins B1, B2, B6, C, E, niacin, carnitine, betaine, folate pantothenic acid, biotin, zinc, iron, calcium, chromium, magnesium, and mixtures thereof. It can be included as.
  • the composition may include a substance having a therapeutic activity against kidney cancer used alone or used in the past.
  • the term "patient” refers to humans, horses, sheep, pigs, goats, and camels having a disease caused by kidney cancer and its direct and indirect causes, and whose symptoms may be improved by administering the composition of the present invention. Means animals such as nutrition, dogs.
  • a composition comprising the extract of as soon as the present invention, the above-mentioned kidney cancer can be effectively prevented and treated.
  • the composition of the present invention can be administered in parallel with existing kidney cancer treatments.
  • the term "administration” means introducing a predetermined substance into a patient by any suitable method, and the route of administration of the composition of the present invention is oral or parenteral via any general route as long as the target tissue can be reached. May be administered.
  • the composition may be administered by any device in which the active agent may migrate to the target cell.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity.
  • the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses.
  • the method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration.
  • the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day.
  • Dosage levels for a particular patient may vary depending on sex, age, health condition, diet, time of administration, method of administration, drug mixture, the condition of the patient, and the extent of the onset of neurological disease.
  • the present invention provides a functional food for preventing kidney cancer containing Cannabis Semen ethanol extract containing a food supplement acceptable food additive as an active ingredient.
  • Functional food of the present invention preferably contains 0.1 to 5% by weight, more preferably 1% by weight of the ethanol extract relative to the total weight.
  • Functional food of the present invention is not particularly limited in the formulation, for example, dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc., and includes all of the health food in the usual sense.
  • “functional food” means a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to Act No. 6767 of the Health Functional Food Act, and “functional” refers to the structure of the human body And ingestion for the purpose of gaining useful effects in health applications such as nutrient regulation or physiological action for function.
  • the present invention As a result of injecting the extract of the present invention into ACHN kidney cancer cells, it was confirmed that the ACHN kidney cancer cells die (see Fig. 1 ). Therefore, it can be seen that the extract as soon as there is a therapeutic effect for kidney cancer.
  • the present invention was completed by preparing a functional food for preventing kidney cancer containing the extract as soon as the active ingredient (see Preparation Example 2 ).
  • the composition for treating renal cancer according to the present invention will be very effective in the treatment of renal cancer patients.
  • FIG. 1 is a result of the Alamar Blue analysis to determine the effect of the introduction of Mazarin in human kidney cancer ACHN cells on the growth of kidney cancer cells.
  • the horizontal axis shows the concentration of the extract, and the vertical axis shows the survival rate of kidney cancer cells.
  • ACHN cells which are human kidney cancer cells
  • the Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.
  • ACHN cells a kidney cancer cell line used in the present invention, were distributed from Korean Cell Line Bank (KCLB) and used for experiments. Specifically, ACHN kidney cancer cells (Minimum essential medium) containing 10% FBS (fetal bovine serum, fetal bovine serum) (Welgene) and 25 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) Subcultured in medium.
  • FBS fetal bovine serum, fetal bovine serum
  • HEPES 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid
  • Example 1 As soon as the extract extracted in Example 1 was confirmed the effect of inhibiting growth against ACHN cells which are kidney cancer cells. Specifically, 6.0 ⁇ 10 per well in a 96 well plate 3 The ACHN kidney cancer cells were seeded and incubated for 24 hours, and then dissolved in dimethyl sulfoxide (DMSO). When the ethanol extract was treated at concentrations of 0 to 100 ⁇ g / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 ⁇ g / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1 and Fig. 1).
  • DMSO dimethyl sulfoxide
  • the relative cell numbers of kidney cancer cells after 48 hours according to the concentrations of the respective treatments based on the number of survival rates of the kidney cancer cells of the control group not treated with mazain were described as 1.
  • the extract of the present invention has excellent ACHN cell killing activity and further demonstrates that it has therapeutic and prophylactic activity for kidney cancer.
  • Acute toxicity test was performed using 6-week-old SPF SD rats. Two animals per group were suspended orally administered at a dose of 5 g / kg, each of which was suspended in 0.5% methylcellulose solution of the extract of Example 1 of the present invention. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed, and autopsy was performed to observe abdominal and thoracic organ abnormalities.
  • kidney cancer treatment effect of the extract as soon as through the above example was prepared for the treatment of kidney cancer containing the extract as an active ingredient as soon as.
  • preparation of the following therapeutic agent can be used for the application of the health food as well as the therapeutic agent.
  • the present inventors confirmed that as soon as the extract extract as soon as the kidney cancer therapeutic activity through the above-mentioned to prepare a functional food containing it as an active ingredient as follows.
  • Chewing gum was prepared using conventional methods using the composition and content of 20% gum base, 76.36 to 76.76% sugar, 0.24 to 0.64% mazarine extract, 1% fruit flavor, and 2% water.
  • composition and content of sugar 34.36 to 34.76%, cocoa butter 34%, cocoa mass 15%, cocoa powder 15%, lecithin 0.5%, vanilla flavor 0.5%, mazarine extract 0.24 to 0.64%, using conventional methods Chocolate was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une nouvelle utilisation d'un extrait de semence de cannabis, et plus particulièrement, une composition pour le traitement du cancer du rein et un aliment fonctionnel contenant, comme ingrédient actif, un extrait de semence de cannabis ayant d'excellents effets prophylactiques et thérapeutiques sur le cancer du rein. L'extrait de semence de cannabis, selon la présente invention, élimine la prolifération des cellules cancéreuses du rein et induit leur apoptose, et peut ainsi être utilisé efficacement dans la prophylaxie et le traitement du cancer du rein.
PCT/KR2012/002469 2011-03-31 2012-04-02 Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis Ceased WO2012134252A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0029445 2011-03-31
KR1020110029445A KR20120111125A (ko) 2011-03-31 2011-03-31 마자인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품

Publications (2)

Publication Number Publication Date
WO2012134252A2 true WO2012134252A2 (fr) 2012-10-04
WO2012134252A3 WO2012134252A3 (fr) 2013-03-07

Family

ID=46932193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002469 Ceased WO2012134252A2 (fr) 2011-03-31 2012-04-02 Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis

Country Status (2)

Country Link
KR (1) KR20120111125A (fr)
WO (1) WO2012134252A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102269816B1 (ko) * 2021-01-19 2021-06-28 주식회사 네이처센스 대마 추출물을 유효성분으로 포함하는 항암, 항암 부작용 저하 및 암 전이 억제용 조성물
WO2023013963A1 (fr) * 2021-08-06 2023-02-09 이재형 Composition pharmaceutique comprenant un extrait d'herbe médicinale composite en tant que principe actif pour la prévention ou le traitement du cancer
KR102559079B1 (ko) * 2021-08-06 2023-07-24 이재형 한약재 복합 추출물을 유효 성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR102887343B1 (ko) * 2024-09-06 2025-11-17 주식회사 에이비파트너스 만성신장질환의 예방 또는 개선용 건강기능식품 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990070229A (ko) * 1998-02-18 1999-09-15 송시훈 종자유 제조방법
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
US20100152238A1 (en) * 2007-03-05 2010-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts

Also Published As

Publication number Publication date
KR20120111125A (ko) 2012-10-10
WO2012134252A3 (fr) 2013-03-07

Similar Documents

Publication Publication Date Title
WO2012134169A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait de semence de gleditsiae
WO2012134252A2 (fr) Composition pour le traitement du cancer du rein et aliment fonctionnel contenant un extrait de semence de cannabis
KR102054437B1 (ko) 조각인 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2012134250A2 (fr) Composition pour le traitement du cancer du rein et composition pour produits cosmétiques contenant un extrait de rhizome de nardostachys
KR20120122410A (ko) 목향 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014069692A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'inula britannica var. chinensis
WO2013147340A1 (fr) Composition et complément alimentaire pour traiter le cancer du poumon, contenant un extrait d'encens
KR20120122405A (ko) 백축 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
KR20120109790A (ko) 유향 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
KR20120109140A (ko) 익지인 추출물을 포함하는 폐암 치료용 조성물 및 건강 기능성 식품
WO2012134167A2 (fr) Composition pour le traitement du cancer du poumon et aliment fonctionnel contenant un extrait d'eriobotriae folium
KR20120111122A (ko) 대계근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120111121A (ko) 구절초 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014069689A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de racine de saussurae
WO2014069691A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de cnidium monnieri
WO2014069695A1 (fr) Composition pour traiter le cancer du pancréas et aliment santé fonctionnel contenant un extrait de boswellia
KR101790742B1 (ko) 시호 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20120122404A (ko) 괄루근 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014069686A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait de racine de trichosanthis
KR20120122415A (ko) 오배자 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
WO2014077433A1 (fr) Composition contenant de l'extrait de semen gleditsiae utilisable pour traiter le cancer du rein et en tant qu'aliment fonctionnel
KR20120122413A (ko) 선복화 추출물을 포함하는 신장암 치료용 조성물 및 건강 기능성 식품
KR20130027064A (ko) 청피 추출물을 포함하는 신장암 치료용 조성물 및 화장료 조성물
WO2014069690A1 (fr) Composition pour traiter le cancer rénal et aliment santé fonctionnel contenant un extrait d'hedyotis diffusa
KR20120021281A (ko) 고량강 추출물을 포함하는 전립선암 치료용 조성물 및 기능성 식품

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12765334

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12765334

Country of ref document: EP

Kind code of ref document: A2